In the latest market close, McKesson (MCK) reached $589.95, with a -0.19% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.04%. Meanwhile, the Dow experienced a drop of 0.15%, and the technology-dominated Nasdaq saw an increase of 0.12%. Heading into today, shares of the prescription drug distributor had gained 6.35% over the past month, outpacing the Medical sector's gain of 2.3% and the S&P 500's gain of 4.15% in that time. Market participants will b ...

McKesson (MCK) closed the most recent trading day at $591.07, moving +1.07% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.23%. At the same time, the Dow lost 0.17%, and the tech-heavy Nasdaq gained 0.34%. The prescription drug distributor's stock has climbed by 6.02% in the past month, exceeding the Medical sector's gain of 2.69% and the S&P 500's gain of 3.96%. Analysts and investors alike will be keeping a close eye on the performance of McKesson in its upcoming earni ...

McKesson (MCK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this prescription drug distributor have returned +6%, compared to the Zacks S&P 500 composite's +4% change. During this period, the Zacks Medical - Dental Supplies industry, which McKesson falls in, has lost 0.6%. The key question now is: What could be the stock's future direction? While medi ...

McKesson (MCK) is witnessing strong momentum, with its shares having rallied 26.3% year to date compared with 1.4% growth of the industry. The S&P 500 composite has risen 7% during the same time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Headquartered in San Francisco, CA, McKesson is a healthcare services and information technology company with two operating segments — Distribution ...

McKessonCorporation (MCK) is well-poised for growth, backed by strategic collaborations and strength in the Distribution Solutions segment. However, the company’s opioid-related litigation expenses are a potential threat. Shares of this Zacks Rank #3 (Hold) company have risen 27.7% year to date compared with the industry’s 1.7% growth. The S&P 500 Index has jumped 12.4% in the same time frame. McKesson is a healthcare services and information technology company with a market capitalization of $76.29 billion ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What ...

McKesson Corporation (MCK) reported fourth-quarter fiscal 2024 adjusted earnings per share (EPS) of $6.18, which missed the Zacks Consensus Estimate of $6.34 by 2.52%. The bottom line also declined 14% on a year- over-year basis. GAAP EPS was $6.02, up 5.4% from the year-ago quarter’s level. Revenue Details Revenues of $76.36 billion missed the Zacks Consensus Estimate by 3%. However, the top line increased 11% year over year, primarily driven by growth in the U.S. Pharmaceutical segment. Full-Years Results ...

For the quarter ended March 2024, McKesson (MCK) reported revenue of $76.36 billion, up 10.8% over the same period last year. EPS came in at $6.18, compared to $7.19 in the year-ago quarter. The reported revenue represents a surprise of -3.00% over the Zacks Consensus Estimate of $78.72 billion. With the consensus EPS estimate being $6.34, the EPS surprise was -2.52%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

McKesson (MCK) came out with quarterly earnings of $6.18 per share, missing the Zacks Consensus Estimate of $6.34 per share. This compares to earnings of $7.19 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of -2.52%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $7.05 per share when it actually produced earnings of $7.74, delivering a surprise of 9.79%. Over the last four quarte ...

公司业务范围 - 公司在美国提供药品分销和物流服务，包括品牌药品、仿制药、特殊药品、生物仿制药和非处方药[4] - 公司的处方技术解决方案部门帮助解决患者的药物获取、负担和依从性挑战，服务于生物制药和生命科学合作伙伴[4] - 公司的医疗外科解决方案部门向医疗保健提供者提供医疗外科用品分销、物流和其他服务[4] - 公司的国际部门在加拿大和欧洲为批发、机构和零售客户提供分销和服务[4] 美国处方药业务 - 公司的美国处方药部门通过27个分销中心为客户提供品牌药品、仿制药、特殊药品、生物仿制药和非处方药的分销和物流服务[4] - 公司的美国处方药部门通过ClarusONE合资企业与Walmart Inc.合作采购仿制药品[4] - 公司的美国处方药部门通过McKesson ConnectSM提供基于互联网的订购系统，提高产品的可用性和订购效率[4] - 公司的美国处方药部门通过Six Sigma方法论优化分销效率和服务准确性[4] 社区药房和健康业务 - 公司的社区药房和健康部门通过Health Mart®提供全国范围的药房特许经营计划，支持独立药房的运营卓越[4] - 公司的社区药房和健康部门通过McKesson Reimbursement AdvantageSM提供全面的报销优化方案，包括金融服务、分析服务和客户服务[4] RxTS业务 - RxTS帮助患者节省了超过88亿美元的品牌和特殊药物费用[26] - RxTS帮助防止了约1070万份处方因支付能力挑战而被放弃[26] - RxTS帮助患者超过9400万次获取药物[26] 公司战略举措 - 我们在2022财年和2023财年剥离了大部分欧洲业务[27] - 我们投资于新的和现有的分销中心，以增加规模和能力，通过自动化和技术提高效率，并增强监管合规能力[28] - 我们在近年来进行了额外的战略举措，旨在提高运营效率，专注于核心医疗业务，执行业务战略，并增强我们的竞争地位[28] 公司风险 - 公司可能面临诸多法律诉讼，包括与分销受控物质相关的问题，可能导致巨额开支和风险[48] - 公司可能受到信息系统或网络问题，可能导致业务中断、客户流失和增加开支[52] - 公司可能受到经济环境变化的不利影响，包括通货膨胀、经济放缓或衰退[65] 财务表现 - 2024财年，公司的营收增长12%，毛利增长4%[95] - 2024财年每股稀释收益为22.39美元，较上一年下降[95] - 公司在2024年度通过股票回购和股息支付向股东返还了33亿美元现金[96]